Hologic Inc

HOLX

Equity

ISIN US4364401012 / Valor 939263

NASDAQ (2024-11-21)

USD 78.72+0.87%

Hologic Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Hologic Inc is a leading global healthcare company focused on improving women's health through innovative medical technologies. The company's Project Health Equity initiative aims to address healthcare disparities by providing access to screenings and treatment for underserved women in clinics nationwide. Hologic's products and services play a crucial role in advancing healthcare outcomes for women around the world.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Hologic Inc. reported revenue of $1,011.4 million for the third quarter of fiscal 2024, marking a 2.7% increase compared to the same period last year. When adjusted for constant currency, the revenue growth was 3.1%. Excluding COVID-19 related revenues, the company's organic revenue grew by 5.8% in constant currency terms.

Earnings Per Share

For the third quarter of fiscal 2024, Hologic Inc. achieved a GAAP diluted earnings per share (EPS) of $0.82, a significant improvement from the previous year's loss of $0.16 per share. On a non-GAAP basis, the diluted EPS was $1.06, which represents a 14.0% increase from the prior year's $0.93 per share.

Segment Performance

Hologic Inc.'s Breast Health segment saw a revenue increase of 6.9%, or 7.1% in constant currency, driven by strong gantry sales and service. The Surgical segment also performed well, with a revenue growth of 5.9%, or 6.2% in constant currency, primarily due to solid sales of MyoSure and Fluent Fluid Management products.

Cash Flow and Share Repurchase

Hologic Inc. reported strong cash flow from operations amounting to $405.7 million for the third quarter of fiscal 2024. Additionally, the company repurchased 1.4 million shares for $100 million, reflecting its commitment to returning value to shareholders.

Financial Guidance

For the fourth quarter of fiscal 2024, Hologic Inc. provided revenue guidance in the range of $970 million to $985 million, representing a growth of 2.6% to 4.2%. The company also projected a GAAP EPS of $0.80 to $0.87 and a non-GAAP EPS of $0.97 to $1.04, indicating continued strong financial performance.

Summarized from source with an LLMView Source

Key figures

9.47%1Y

4.50%3Y

59.0%5Y

Performance

17.3%1Y

22.2%3Y

29.8%5Y

Volatility